Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Destroying Diabetes?

Diabetics could one day live lives free of needles and implants thanks to a new treatment that can prompt the body to generate new insulin-producing cells. Researchers Aaron Vinik of Eastern Virginia Medical School and Lawrence Rosenberg of McGill University discovered that a fragment of a protein known as INGAP stimulates cells in the pancreas of adult animals to develop into “islet” cells that make insulin in response to blood sugar. In animal experiments, a few weeks of daily injections of the protein segment yielded normal blood sugar and insulin levels. GMP of Fort Lauderdale, FL, which licensed the technology, has started human trials in patients with both Type 1 (juvenile) and Type 2 (adult onset) diabetes. The treatment could become available in about five years. One question that remains is whether Type 1 diabetics, whose bodies have destroyed their own islet cells, would be able to sustain the new cells without immune suppression.

0 comments about this story. Start the discussion »

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me